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Letters e23Perhaps a similar mechanism may explain the
translucent, tight, and parchment paperelike
‘‘collodion membrane’’ in our patient after prenatal
exposure to infliximab. Collodion membrane
secondary to ichthyoses can be excluded because
this child’s condition was self-limited. Considering
potential side effects of alternative systemic
agents, TNF-alfa inhibitors should remain in the
armamentarium for pregnant psoriatic patients.
Etanercept may be the safest of this class because
of its lower level transplacental passage.
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chemotherapy for radiation-induced
osteosarcoma
To the Editor: Chemotherapeutic agents have
numerous cutaneous adverse effects, including
hyperpigmentation, radiation recall, and extravasa-
tion injuries. Typically, hyperpigmentation reactions
are either diffuse (eg, the ‘‘busulfan tan’’) or localized
(eg, streaking over veins in fluorouracil).1 We
describe a patient that developed hyperpigmenta-
tion following chemotherapy for a radiation-induced
osteosarcoma.
A 47-year-old African Americanman presented for
management of a radiation-induced osteosarcoma.
Intracranial meningioma was originally diagnosed
and treated with a craniotomy in 1995, followed by
resection of recurrent meningioma in 1996 and
adjuvant radiation in 1999. In 2012, he presented
with an enlarging right orbital rim mass that was
treated with a craniotomy and orbitotomy. Pathology
showed osteoblastic osteosarcoma, likely secondary
to radiation therapy. His chemotherapy regimen
included 2 months of Adriamycin (doxorubicin)
and cisplatin, followed by methotrexate, ifosfamide,
and etoposide. Seventy-two hours following his
second dose of methotrexate, minimally pruritic
cutaneous changes developed on his lower extrem-
ities, which spread to the extensor arms and trunk.
Physical examination demonstrated symmetric
fine reticular and linear hyperpigmentation without
excoriations on the dorsal ankles, medial arms,
abdomen, and back, which on dermatoscopic
exam appeared to be surrounded by a halo of
erythematous macules (Fig 1, A). Punch biopsy
demonstrated epidermal dysmaturation with
numerous atypical keratinocytes and melanin depo-
sition within the epidermis and stratum corneum
(Fig 1, B). Given the mild inflammatory infiltrate
and melanin deposition, we treated with 0.1%
triamcinolone cream twice daily to reduce the
inflammation and lighten the pigment by inhibiting
melanocyte secretory function, similar to treatment
of postinflammatory hyperpigmentation. The lesions
resolved within 6 months.
Although a similar reticular, hyperpigmented
pattern has not been reported in association with
Fig 1. A, Drug reaction. Linear and reticulated areas of hyperpigmentation on the abdomen.
B, Drug reaction. Hematoxylin and eosin section showing a mildly atrophic epidermis with
focal basal vacuolar change. There is dysmaturation of the keratinocytes likely related
to chemotherapy effect. Melanin is present within the stratum corneum. Within the dermis a
scant infiltrate of lymphocytes surround the superficial vessels and there are scattered
melanophages.
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patient, a similar eruption has been described previ-
ously in association with cyclophosphamide and
5-fluorouracil.2,3 The comparable mechanism of ac-
tion of ifosfamide compared with cyclophospha-
mide may have resulted in a similar eruption.2
However, the cyclophosphamide pigmentation re-
ported was more patchy and coarse than seen in our
patient. A potential mechanism resulting in this
peculiar pattern of hyperpigmentation may be local
vascular inflammation and subsequent postinflam-
matory pigmentary alteration. Although minor pru-
ritus was associated with the eruption, the pattern of
skin changes did not correspond to those areas that
weremost itchy. The patient was also on other drugs,
but they had been used for an extended time and
have not been reported to result in similar cutaneous
changes.
We suspect the cutaneous eruption was due to the
combination of methotrexate, ifosfamide, and eto-
poside. It appears most temporally related to meth-
otrexate, although this is not conclusive of causality.
Our patient received another round of chemo-
therapy 1 month later without further exacerbation.
The anti-inflammatory effect from the continued use
of triamcinolone cream may have prevented recur-
rence. Interestingly, a report describing a similar
hyperpigmented pattern following treatment with
5-fluorouracil also described lack of recurrence
despite continued use of the causative drug at the
same dosage.3 Our case resolved with intermediate-
strength topical steroid treatment, which should
provide reassurance and prevent unnecessary bi-
opsies in patients who present with similar findings.
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Occurrence of psoriatic plaques on previous
adalimumab injection sites during disease
relapse in a patient with pustular psoriasis
To the Editor: Psoriasis has been reported after tumor
necrosis factor (TNF) inhibitor treatment in patients
with rheumatic diseases.1 Recently, we observed a
patient with pustular psoriasis in whom psoriatic
plaques developed on previous adalimumab injec-
tion sites during disease relapse.
This 45-year-old man suffered from severe acro-
dermatitis continua for 25 years and had initially
